Therapeutic potential of platelet-activating factor antagonism in the management of myocardial infarction

Canadian Journal of Cardiology

Volumn 16, Issue 4, 2000, Pages 497-504

  Loucks, Eric B ^a   Qayumi, A Karim ^a,b   Godin, David V ^a   English, John C ^a   Lim, Seung Pyung ^b   Al Mahmeed, Taghreed ^b   Gul, Shahid ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Ischemia; Myocardial infarction; Reperfusion; Reperfusion injury

Indexed keywords

3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; NONHUMAN; REPERFUSION INJURY; SCAR FORMATION; SWINE;

ANIMALS; FEMALE; ISOQUINOLINES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; PLATELET AGGREGATION INHIBITORS; PYRIDINIUM COMPOUNDS; RANDOM ALLOCATION; SWINE; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 0034011196     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wilcox RG, von der Lippe G, OLsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;ii:525-30.
2. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;i:397-402.
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;ii:349-60.
4. Mauri F, DeBiase A, Franzosi M, Pampallona S, Foresti A, Gasparini M. Analisi dele casue di morte introspedaliera. G Ital Cardiol 1987;17:37-44.
5. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311-22.
6. Qayumi AK, Jamieson WRE. Pathophysiology of reperfusion injury in organ transplantation. In: Das DK, ed. Pathophysiology of Reperfusion Injury. Ann Arbor: CRC Press, 1993:325-63.
7. Maza SR, Frishman WH. Therapeutic options to minimize free radical damage and thrombogenicity in ischemic/reperfused myocardium. Am Heart J 1987;114:1206-15.
8. Qayumi AK, English JC, Godin DV, et al. The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury. Ann Thorac Surg 1998;65:1690-7.
9. Miyazaki S, Fujiwara H, Onodera T, et al. Quantitative analysis of contraction band and coagulation necrosis after ischemia and reperfusion in the porcine heart. Circulation 1987;75:1074-82.
10. Jennings RB, Steenbergen C Jr, Reimer KA. Myocardial ischemia and reperfusion. Monogr Pathol 1995;37:47-80.
11. Zar JH. Biostatistical Analysis, 3rd edn. Upper Saddle River: Prentice Hall, 1996.
12. Sawa Y, Schaper J, Roth M, et al. Platelet-activating factor plays an important role in reperfusion injury in myocardium. Efficacy of platelet-activating factor receptor antagonist (CV-3988) as compared with leukocyte-depleted reperfusion. J Thorac Cardiovasc Surg 1994;108-.953-9.
13. Ko W, Lang D, Hawes AS, Zelano JA, Isom W, Krieger KH. Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion. J Surg Res 1993;55:504-15.
14. Montrucchio G, Alloatti G, Mariano F, et al. Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart. Am J Pathol 1993;142:471-80.
15. Loucks EB, Symersky P, Qayumi AK. Platelet-activating factor antagonism: a new concept in the management of regional myocardial ischemia-reperfusion injury. J Invest Surg 1997;10:321-38.
16. Delbridge LM, Stewart AG, Goulter CM, Morgan TO, Harris PJ. Platelet-factivating actor and WEB-2086 directly modulate rat cardiomyocyte contractility. J Mol Cell Cardiol 1994;26:185-93.
17. Piper PJ, Stewart AG. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists. Br J Pharmacol 1987;90:771-83.
18. Izumi T, Shimizu T. Platelet-activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta 1995;1259:317-33.
19. Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science 1982;218:286-9.
20. Naslund U, Haggmark S, Johansson G, Marklund SL, Reiz S, Oberg A. Superoxide dismutase and catalase reduce infarct size in a porcine myocardial occlusion-reperfusion model. J Mol Cell Cardiol 1986;18:1077-84.
21. + antiporter inhibitor on postischemic reperfusion in pig heart. J Cardiovasc Pharmacol 1994;23:72-8.
22. Ma X-L, Weyrich AS, Krantz S, Lefer AM. Mechanisms of the cardioprotective actions of WEB-2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion. J Pharmacol Exp Ther 1992;260:1229-36.
23. Reichenbach D, Cowan MJ. Healing of myocardial infarction with and without reperfusion. In: R Virmani, JB Atkinson, JJ Fenoglio, eds. Cardiovascular Pathology. Philadelphia: WB Saunders Co, 1991:86-99.